Exploring Key Unmet Needs in Idiopathic Pulmonary Fibrosis

Paul Noble, MD, opens a discussion surrounding the current treatment landscape and key elements to address in the management of idiopathic pulmonary fibrosis.

Paul Noble, MD, analyzes variables contributing to IPF or PPF disease prognosis.

Paul Noble, MD, discusses epidemiology facts, differential diagnosis, and arriving at a IPF or PPF diagnosis.

Paul Noble, MD, discusses the importance of early diagnosis in patients with IPF or PPF.

Dr. Paul Frohna discusses the importance of non-pharmacological modalities, as well as utilizing multidisciplinary care, for patients with idiopathic and progressive pulmonary fibrosis.

An expert pulmonologist discusses the best ways to manage acute exacerbations and the psychosocial component of idiopathic and progressive pulmonary fibrosis.

Dr. Frohna covers unmet needs in the latest treatment guidelines and therapies used to combat idiopathic and progressive pulmonary fibrosis.

Paul Noble, MD, discusses the roles of biomarker testing and HRCT in IPF and PPF.

Paul Noble, MD, provides his final thoughts surrounding unmet needs and breakthrough strategies for detection of IPF.

An expert lung doctor covers the main adverse events associated with antifibrotic agents and why it is necessary to develop newer pharmacotherapies to treat idiopathic and progressive pulmonary fibrosis.

Dr Frohna discusses some therapies under investigation for idiopathic and progressive pulmonary fibrosis, including one targeting the PDE4 pathway.

An expert physician discusses the potential role of novel agents in the management of idiopathic and progressive pulmonary fibrosis.

Paul W. Noble, M.D., of Cedars-Sinai in Los Angeles, and Paul Frohna, M.D., Ph.D., of Endeavor BioMedicines, discussed the symptoms, epidemiology diagnosis and treatment of idiopathic pulmonary fibrosis (IPF) in a Managed Healthcare Executive K-Cast video series.